Discovering a novel drug class targeting the epitranscriptomics machinery - Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting the epitranscriptomics machinery.
Location: United States, New York
Total raised: $54M
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.10.2018 | Series A | $54M | Forbion |
Mentions in press and media 6
| Date | Title | Description | Source |
| 10.10.2018 | Forbion Co-leads $54m Series A Financing in newly formed Got... | Gotham is developing a novel drug class targeting RNA-modifying proteins Forbion’s first investment ... | forbion.co... |
| 10.10.2018 | RNA metabolism-focused Gotham Therapeutics launches with $54... | The company’s approach centers on the emerging field of epitranscriptomics, a field of study within ... | medcitynew... |
| 10.10.2018 | Gotham Therapeutics Raises $54M in Series A Funding | Gotham Therapeutics, a NYC-based biotechnology company developing a novel drug class targeting RNA-m... | finsmes.co... |
| 10.10.2018 | Gotham Therapeutics Launches with $54M Series A | NEW YORK, NY, Biotechnology company developing a novel drug class targeting RNA-modifying proteins... | vcnewsdail... |
| 10.10.2018 | Gotham Therapeutics Launches with $54 Million Series A | NEW YORK--(BUSINESS WIRE)--Gotham Therapeutics, a biotechnology company developing a novel drug clas... | citybizlis... |
| - | RNA metabolism-focused Gotham Therapeutics launches with $54... | A company developing a class of RNA-modifying proteins to potentially treat cancers, autoimmune diso... | medcitynew... |